Valproate showed no clear difference in dropout rate ‐ All‐cause At 3‐12 weeks (secondary acceptability… compared with olanzapine (high certainty).
Valproate may leads to lower response rate at 8 weeks (primary efficacy outcome) compared with risperidone (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether valproate changes adverse events ‐ Sedation At 8 weeks (secondary tolerability outcome) compared with risperidone (very low certainty).
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3‐8 weeks (secondary… compared with placebo (high certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause (secondary acceptability outcome) At 5 ‐ 12… compared with risperidone (low certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause 3‐8 weeks (secondary acceptability outcome) compared with placebo (moderate certainty).
It is very uncertain whether valproate changes response rate at 4 weeks (primary efficacy outcome) compared with placebo (very low certainty).
It is very uncertain whether valproate changes number with any adverse event at 4 weeks (primary tolerability… compared with placebo (very low certainty).
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 4 weeks (secondary… compared with placebo (very low certainty).
Family therapy may leads to higher remission post‐intervention compared with standard care/treatment (low certainty).
It is very uncertain whether family therapy changes remission post‐intervention compared with psychological interventions (very low certainty).
It is very uncertain whether family therapy changes remission at long‐term compared with educational interventions (very low certainty).
It is very uncertain whether any early psychological intervention changes PTSD diagnosis: post‐treatment compared with waiting list/usual care (very low certainty).